Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 23994632)

1.

Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer.

Xiao W, Wang J, Ou C, Zhang Y, Ma L, Weng W, Pan Q, Sun F.

Biochem Biophys Res Commun. 2013 Sep 20;439(2):167-72. doi: 10.1016/j.bbrc.2013.08.071. Epub 2013 Aug 28.

PMID:
23994632
2.

Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer.

Wang J, Ma L, Weng W, Qiao Y, Zhang Y, He J, Wang H, Xiao W, Li L, Chu Q, Pan Q, Yu Y, Sun F.

Hepatology. 2013 Sep;58(3):1011-20. doi: 10.1002/hep.26420. Epub 2013 Jul 16.

PMID:
23532963
3.

MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer.

Li L, Wang J, Zhang Y, Zhang Y, Ma L, Weng W, Qiao Y, Xiao W, Wang H, Yu W, Pan Q, He Y, Sun F.

FEBS Lett. 2013 Dec 11;587(24):3921-7. doi: 10.1016/j.febslet.2013.10.042. Epub 2013 Nov 7.

4.

Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells.

Zhang T, Zhang J, You X, Liu Q, Du Y, Gao Y, Shan C, Kong G, Wang Y, Yang X, Ye L, Zhang X.

Hepatology. 2012 Dec;56(6):2051-9. doi: 10.1002/hep.25899. Epub 2012 Nov 13.

PMID:
22707013
5.
6.

Targeting YAP and Hippo signaling pathway in liver cancer.

Liu AM, Xu MZ, Chen J, Poon RT, Luk JM.

Expert Opin Ther Targets. 2010 Aug;14(8):855-68. doi: 10.1517/14728222.2010.499361. Review.

PMID:
20545481
7.

YAP activation is an early event and a potential therapeutic target in liver cancer development.

Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S, Columbano A.

J Hepatol. 2014 Nov;61(5):1088-96. doi: 10.1016/j.jhep.2014.06.033. Epub 2014 Jul 7.

PMID:
25010260
8.

Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer.

Wang J, Wang H, Zhang Y, Zhen N, Zhang L, Qiao Y, Weng W, Liu X, Ma L, Xiao W, Yu W, Chu Q, Pan Q, Sun F.

Cell Signal. 2014 May;26(5):1048-59. doi: 10.1016/j.cellsig.2014.01.022. Epub 2014 Jan 25.

PMID:
24468535
9.

Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma.

Huo X, Zhang Q, Liu AM, Tang C, Gong Y, Bian J, Luk JM, Xu Z, Chen J.

Oncol Rep. 2013 Feb;29(2):840-6. doi: 10.3892/or.2012.2176. Epub 2012 Dec 10.

PMID:
23232767
10.

RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.

Ahn EY, Kim JS, Kim GJ, Park YN.

Mol Cancer Res. 2013 Jul;11(7):748-58. doi: 10.1158/1541-7786.MCR-12-0665. Epub 2013 Apr 17.

11.

Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.

Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, Sticht C, Tomasi ML, Delogu S, Evert M, Fan B, Ribback S, Jiang L, Brozzetti S, Bergmann F, Dombrowski F, Schirmacher P, Calvisi DF, Breuhahn K.

Gastroenterology. 2013 Jun;144(7):1530-1542.e12. doi: 10.1053/j.gastro.2013.02.009. Epub 2013 Feb 16.

12.

Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.

Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X, Zhang X, Zhang F, Chen H, Liu Y, Jiang Y, Sun S, Zheng Y, Li N, Huang L.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):E89-98. doi: 10.1073/pnas.1319190110. Epub 2013 Dec 23.

13.

Differences in Yes-associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma.

Wang C, Zhang L, He Q, Feng X, Zhu J, Xu Z, Wang X, Chen F, Li X, Dong J.

Mol Med Rep. 2012 Feb;5(2):410-4. doi: 10.3892/mmr.2011.640. Epub 2011 Oct 19.

PMID:
22012126
14.

Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice.

Kowalik MA, Saliba C, Pibiri M, Perra A, Ledda-Columbano GM, Sarotto I, Ghiso E, Giordano S, Columbano A.

Hepatology. 2011 Jun;53(6):2086-96. doi: 10.1002/hep.24289. Epub 2011 May 13.

PMID:
21391223
15.

Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.

Zhou Z, Hu T, Xu Z, Lin Z, Zhang Z, Feng T, Zhu L, Rong Y, Shen H, Luk JM, Zhang X, Qin N.

FASEB J. 2015 Feb;29(2):724-32. doi: 10.1096/fj.14-262980. Epub 2014 Nov 10.

PMID:
25384421
16.

Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP.

Miao HL, Pan ZJ, Lei CJ, Wen JY, Li MY, Liu ZK, Qiu ZD, Lin MZ, Chen NP, Chen M.

J Cell Biochem. 2013 Mar;114(3):625-31. doi: 10.1002/jcb.24404.

PMID:
23060277
17.

The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain.

Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):E2441-50. doi: 10.1073/pnas.1212021109. Epub 2012 Aug 13.

18.

Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53.

Bai N, Zhang C, Liang N, Zhang Z, Chang A, Yin J, Li Z, Luo N, Tan X, Luo N, Luo Y, Xiang R, Li X, Reisfeld RA, Stupack D, Lv D, Liu C.

Cancer Biol Ther. 2013 Jun;14(6):511-20. doi: 10.4161/cbt.24345.

19.

The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.

Yi C, Shen Z, Stemmer-Rachamimov A, Dawany N, Troutman S, Showe LC, Liu Q, Shimono A, Sudol M, Holmgren L, Stanger BZ, Kissil JL.

Sci Signal. 2013 Sep 3;6(291):ra77. doi: 10.1126/scisignal.2004060.

20.

Arsenic-induced cutaneous hyperplastic lesions are associated with the dysregulation of Yap, a Hippo signaling-related protein.

Li C, Srivastava RK, Elmets CA, Afaq F, Athar M.

Biochem Biophys Res Commun. 2013 Sep 6;438(4):607-12. doi: 10.1016/j.bbrc.2013.08.008. Epub 2013 Aug 11.

PMID:
23942117
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk